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Abstract
Background: The aim of the study is to compare the profiles of antibodies (IgM and IgG) against oxidized low-density
lipoprotein (oxLDL) of hematological diseases.
Methods: The serum antibodies of oxLDL-IgM and oxLDL-IgG for 446 cases with hematological diseases and 90
patients with primary hypertension and 90 healthy controls were measured by enzyme-linked immunosorbent
assay (ELISA) in a cross-section survey. The association of serum oxLDL-LgM and oxLDL-IgG with hematological
diseases was analyzed by multiple linear regression model.
Results: Comparing with the hypertension or normal groups, the levels of TCH, TG, LDL-c, HDL-c, oxLDL, and
oxLDL-IgG were lower and the levels of ADP and oxLDL-IgM were higher in the hematological diseases group.
The levels of oxLDL-IgG antibodies titer were different among hematological diseases group. The results of
correlation and multiple regression analysis showed that the seven hematological disease subgroups were
positively related to the oxLDL-IgM antibody titer but negatively related to the oxLDL-IgG antibody titer,
having been adjusted for potential confounding factors such as age, SBP, DBP, BMI, TCH, TG, ADP, oxLDL,
HDL-c, LDL-C.
Conclusions: Here we show that oxLDL-IgG antibodies titer were lower and of oxLDL-IgM titer were higher
than hypertension and healthy individuals. Also oxLDL-IgG titer were different among hematological diseases
group.
Keywords: Oxidized low-density lipoprotein, Autoantibody, Hematological diseases, oxLDL-IgG antibody,
oxLDL-IgM antibody
Background
Oxidized low-density lipoprotein (oxLDL) consists of
lipids, including cholesterol and oxysterols, phospho-
lipids, oxidized fatty acids, aldehydes and lipid peroxides
[1]. Studies have shown that oxLDL plays a major role in
initiation and progression of atherosclerosis (AS) [2].
OxLDL has both proinflammatory and cytotoxic proper-
ties [3]. The relationship was firstly confirmed in the
setting of hypercholesterolemia, with the highest IgM
levels showing the lowest risk of coronary artery disease
for the same level of hypercholesterolemia [4]. An epi-
demiological cohort of initially healthy subjects shows
that IgG and IgM are not only independent predictors of
coronary artery disease (CAD) events but also may mod-
ify CAD risk associated with elevated levels of oxidative
biomarkers [5]. Interestingly, as early to be observed a
high level of serum cholesterol may increase the risk of
atherosclerosis, and a low level of serum cholesterol may
increase the risk of cancer.
Recently, a genetic study showed the molecular basis
of these connections, which indicated that lipid metabol-
ism genes are important for transformation and are up-
regulated in cancer and atherosclerosis. The genes of ac-
tivation oxLDL and its receptor are a molecular connec-
tion between cancer and atherosclerosis [6]. Natural
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antibodies play an important role in the process of
homeostatic inflammation, cell death and apoptotic cell
clearance [7]. Natural IgM antibodies (nIgM) can re-
move oxLDL. The levels of nIgM specific for phosphoryl
choline (anti-PC), were significantly higher in rheuma-
toid arthritis (RA) patients than osteoarthritis (OA) pa-
tients (P < 0.05), and that implicates the deficiency in
immune responses to oxLDL which may contribute to the
metabolic syndromes in the development of OA [8]. Posi-
tive immunoglobulin (Ig)G anticardiolipin antibody
(IgGaCL) was the main component of oxLDL antibody.
One research showed that the IgGaCL was associated with
splanchnic vein thrombosis [9]. Moreover, some investiga-
tors found that the roles of anti-OxLDL antibodies (IgG/
IgM) are related to atherosclerosis and relevant diseases
[10–13]. The human natural monoclonal IgM antibody
SAM-6 is related to apoptosis of cancer cells [14]. We
found that a decreased oxLDL and oxLDL-lgG and the el-
evated oxLDL-lgM serum levels may be related to the de-
velopment and progression of esophageal squamous cell
carcinoma [15].
As far as we know, a few papers reported the rela-
tionship between lipid and leukemia diseases. One re-
port showed that the serum cholesterol, LDL, and
HDL are significantly reduced in myelodysplastic syn-
drome (MDS) patients [16]. Another report showed that
chronic lymphocytic leukemia (CLL) cells are antigen-
experienced which may be derived from self-reactive nat-
ural Ab-producing B cells [17]. Our previous work found
a decreased oxLDL-IgG and an elevated oxLDL-IgM
serum levels in adult with acute myeloblastic leukemia
(AML) [18]. A study with very enlightening significance
showed that a 54-year-old female patient who had sys-
temic lupus erythematosus with marrow fibrosis, when
treated with high dose of steroids and intravenous
immunogloblulin got remission with normalization of
the bone-marrow [19]. So far little information of
oxLDL antibodies is available about hematological dis-
eases, especially for leukemia.
The presence of oxLDL and autoantibodies in several
hematological diseases, particularly in those with very
poor prognosis, and the occurrence of these diseases is
still not clear. The main goal of the present study is to in-
vestigate the profiles of oxLDL, oxLDL-IgG and oxLDL-Ig
antibodies in some hematological diseases and compared
with healthy and primary hypertension patients.
Methods
Subjects
We carried out a cross-sectional study including 286
cases that were first diagnosed according to the WHO
diagnosis criteria during the period from Jan. 2008 to
Feb. 2013 in the department of hematology, Qilu Hos-
pital, Shandong University. Among them, 98 cases were
diagnosed with non-lymphatic leukemia, 60 cases with
lymphatic leukemia, 52 cases with hemolytic anemia, 66
cases with immunothrombocytopenia, 57 cases with
multiple myeloma, 58 cases with non-Kochkin’s lymph-
oma, 55 cases with myelodysplastic syndrome. Two
groups were classified: the first group included 90
patients with primary hypertension diagnosed in the
Division of Cardiology of the Qilu Hospital of Shandong
University, and the second group comprised of 90
consecutive healthy normotensive persons serving as
normal controls from a community screening examin-
ation of health care during the same period. Inclusion
criteria were negative family history of CAD, myocar-
dial infarction (MI), and stroke; nonsmoking status;
and absence of hypercholesterolemia, hypertriglyc-
eridemia, and diabetes mellitus. The Medical Ethics
Committee of Qilu Hospital of Shandong University
approved the study protocol, and written consent was
obtained from each participant.
Measurements
A survey of the characteristics of the subjects, involving
name, gender, age, occupation, etc., was conducted using
a questionnaire. Blood pressure was measured by mer-
cury sphygmomanometer using Korotkoff phase V for
diastolic, according to the WHO guidelines. Hyperten-
sion was defined as systolic pressure ≥140 mm Hg and/
or diastolic pressure ≥90 mm Hg or use of any antihy-
pertensive agents.
Blood sampling and biochemical analysis
Venous blood samples were taken in the morning after an
overnight fast for at least 12 h. The samples were taken
from the femoral artery and immediately centrifuged at
3000 rpm for 10 min. The specimens were then frozen
and kept at −80 °C until assay. Total cholesterol (TCH),
high density lipoprotein cholesterol (HDL-c), triglycerides
(TG) levels were measured with conventional methods.
Low density lipoprotein cholesterol (LDL-c) was cal-
culated by the Fried Ewald formula (LDL ‐ c) =
TCH–(HDL ‐ c) ‐ TG/5. Serum adiponectin (ADP),
oxLDL, oxLDL-IgG and oxLDL-IgM autoantibodies
against-oxLDL measured by the enzyme-linked im-
munosorbent assay (ELISA) with commercially avail-
able kits (Adliteram diagnostic laboratories Ln.,
USA). The detail methods of oxLDL-IgG and oxLDL-
IgM measurements were shown in our previous re-
ports [15, 18]. OxLDL-lgG or oxLDL-lgM titers were
calculated by constructing a standard curve according
to the standards attached in the corresponding kits.
These kits used the individually poached microplate
strips that were coated with native or antigen; as a
result, the antigen stability was shown to be longer
than 4 months at least. In our work, the intra-assay
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and inter-assay reproducibility (coefficients of variation) of
the assay were 3–5 % and 4–7 % respectively.
Statistical analysis
Shapiro-Wilk’s W test of normality was used for data
distribution analysis. The normality distributed data
were expressed as the mean value ± SD. In the univariate
analysis, multiple group comparisons were performed by
one-way analysis of variance (ANOVA), and the signifi-
cant differences between groups were assessed by
Bonferroni test. A bivariate correlation analysis was con-
ducted by the Spearman’s rank method. A generalized
linear regression model was analyzed considering the
main effects of the oxLDL-IgM and oxLDL-IgG titer and
covariates (confounding factors) including gender, age,
body index (BMI), systolic blood pressure (SBP), dia-
stolic blood pressure (DBP), TCH, TG, HDL-c, LDL-c,
and ADP. The subgroup of the hematologic diseases
was denoted as below: 1 = cases with non-lymphatic
leukemia, 2 = cases with lymphatic leukemia, 3 = cases
with hemolytic anemia, 4 = cases with immunothrom-
bocytopenia, 5 = cases with multiple myeloma, 6 =
cases with non Kochkin’s lymphoma, 7 = cases with
myelodysplastic syndrome. The Levene test for homo-
geneity of variance and Bartlett’s spherical test were
carried out using the generalized linear model. In the
analysis a two-tailed P value < 0.05 was considered as
the statistical significance. All statistical analyses were
done by SPSS19.0.
Results
We first measured the oxLDL-IgG and oxLDL-IgG anti-
body titers in a small pre-experiment. On the basis of
these results, we calculated the sample size about 30 ~
50 cases in each group so as to detect the main difference
of each antibody titers with a statistical power of 9 % at
the 0.05 level (the calculation formula was n = 2((tα/2 +
tβ)
^ 2σ^ 2)/δ^ 2, tα/2 = 1.96, β = 0.1, σ = 9.0, δ = 6 ‐ 8). The
overall sample size of the study was at least 495 subjects.
Finally we enrolled 626 subjects in this study.
Table 1 lists baseline characteristics of all subjects.
The differences on the variables of age, systolic blood
pressure and diastolic blood pressure are statistically
significant among those groups. All these variables as
covariates (confounding variables) are included in the
multi linear regression model.
Comparison of the levels of serum lipids between
hypertension group and normal control group
As shown by Tables 2 and 3, the levels of serum TCH,
TG, LDL-c, ADP and oxLDL-IgM in the hypertension
group are higher than those in the normal control
group. Comparing with the controls, the levels of HDL-
c, oxLDL and oxLDL-IgG in the hypertension group are
lower, in particular the difference of oxLDL level is sta-
tistically significant (P < 0.005).
Comparison of the levels of serum blood lipids between
the hypertension group and the hematological diseases
subgroups
Comparing with the hypertension group (⑧), the levels
of serum TCH, TG, LDL-c, HDL-c, oxLDL, oxLDL-IgG
and oxLDL-IgM are lower in the seven subgroups of pa-
tients with hematological diseases. For oxLDL-IgM ex-
cept the immunothrombocytopenia subgroup (④), the
levels of oxLDL-IgM titer are significantly higher than
that in the hypertension group, while the levels of serum
oxLDL-IgG in the seven subgroups (from ① to ⑦ shown
in Table 2) of hematological diseases are lower than that
in the hypertension group (P < 0.005).
Table 1 Demographic and clinical features of the subjects in the study
Group Gender (M/F) Age BMI SBP* DBP+
cases with non lymphatic leukemia 49/49 43.2 ± 18.18 23.2 ± 3.36 126.0 ± 16.33 68.9 ± 12.05
cases with lymphatic leukemia 25/35 31.1 ± 15.40 23.0 ± 3.60 123.1 ± 9.30 79.3 ± 6.2
cases with Hemolytic anemia 30/22 50.5 ± 20.40 23.7 ± 3.99 133.8 ± 19.62 66.1 ± 10.04
cases with immunothrombocytopenia 25/41 43.7 ± 17.37 22.5 ± 3.11 123.7 ± 13.54 76.9 ± 9.99
cases with multiple myeloma 32/25 57.3 ± 8.49 24.9 ± 2.73 135.0 ± 13.28 81.3 ± 12.24
cases with non Kochkin’s 22/36 48.4 ± 12.45 26.6 ± 4.36 109.7 ± 11.49 73.6 ± 8.97
cases with myelodysplastic syndrome 25/30 61.9 ± 13.57 25.1 ± 3.67 122.2 ± 13.10 67.7 ± 10.15
patients with primary hypertension 47/43 56.5 ± 10.87 25.8 ± 3.49 159.2 ± 17.15 94.2 ± 11.03
healthy normal persons+ 40/50 45.4 ± 11.67 24.5 ± 3.35 115.3 ± 16.31 78.2 ± 10.03
F/x2 10.724 16.662 4.766 40.045 30.959
P 0.218 <0.001 0.02 <0.001 <0.001
*: SBP systoilic blood pressure, +: DBP diastolic blood pressure
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Table 2 The distribution of lipid profile in the nine sub groups of the study
Serial number + group CTH TG APD HDL-C LDL-C oxLDL oxLDL-IgG oxLDL-IgM
① cases with non lymphatic leukemia 4.00 ± 1.018 1.64 ± 1.055 7.56 ± 9.976 0.68 ± 0.355 2.97 ± 0.991 31.48 ± 21.594 38.57 ± 19.483 18.70 ± 10.510
② cases with lymphatic leukemia 3.90 ± 1.358 1.44 ± 0.910 2.40 ± 1.089 1.14 ± 0.834 2.47 ± 1.158 21.76 ± 10.846 28.14 ± 19.185 20.24 ± 9.915
③ cases with Hemolytic anemia 3.07 ± 0.805 1.62 ± 1.352 6.58 ± 8.409 0.92 ± 0.481 2.13 ± 1.079 21.08 ± 9.871 31.98 ± 20.364 23.89 ± 9.081
④ cases with immunothrombocytopenia 4.50 ± 0.866 1.24 ± 0.419 4.59 ± 6.395 0.96 ± 0.956 3.28 ± 1.047 17.33 ± 4.716 45.96 ± 25.804 17.74 ± 9.512
⑤ cases with multiple myeloma 4.13 ± 1.829 1.60 ± 0.903 5.08 ± 7.687 0.44 ± 0.312 3.51 ± 1.526 25.39 ± 12.593 61.82 ± 33.245 17.97 ± 6.918
⑥ cases with non Kochkin’s 5.50 ± 1.273 2.16 ± 1.062 5.49 ± 8.018 1.24 ± 1.141 3.82 ± 1.073 24.47 ± 18.673 38.25 ± 19.241 21.58 ± 14.194
⑦ cases with myelodysplastic syndrome 3.83 ± 0.854 1.19 ± 0.352 14.25 ± 12.550 0.70 ± 0.799 2.89 ± 0.427 52.68 ± 33.884 21.93 ± 10.368 23.17 ± 12.745
⑧ patients with primary hypertension 5.78 ± 1.2223 1.58 ± 0.952 5.57 ± 7.457 1.04 ± 0.560 4.43 ± 1.401 25.83 ± 10.735 82.18 ± 10.117 10.31 ± 9.130
⑨ healthy normal persons 5.09 ± 0.568 1.35 ± 1.167 3.28 ± 4.068 1.52 ± 1.169 3.36 ± 1.281 38.91 ± 15.514 77.59 ± 7.165 8.82 ± 9.685
F 42.104 5.424 11.225 12.234 24.532 24.963 100.115 17.313
P <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001














Comparison of the levels of serum blood lipids between
the normal control group and the hematological diseases
subgroups
In the Tables 2 and 3 are the results of multiple group
comparison and post hoc Bonferroni’s test for individual
group-wise comparison of the profiles of lipid in the
study. Compared with ⑨, the levels of oxLDL-IgG
antibodies titer significantly increased, and the oxLDL-
IgM titer decreased, and except ⑥, plasma CTH levels
significant decline in the subsets (from ① to ⑦) of the
hematological diseases group (P < 0.001). Except ①,
plasma oxLDL levels in ⑦ was higher and in the others
subsets of the hematological diseases group was lower
than in ⑨ (P < 0.05).
Table 3 The post hoc Bonferroni’s test for individual group-wise comparisons in Table 2
(I) group (J) group CTH TG APD HDL LDL oxLDL oxLDL-IgG oxLDL-IgM
① ② 1.000 1.000 0.002 0.015 0.305 0.020 0.032 1.000
③ <0.001 1.000 1.000 1.000 0.001 0.015 1.000 0.144
④ 0.247 0.339 0.638 1.000 1.000 <0.001 0.545 1.000
⑤ 1.000 1.000 1.000 1.000 0.217 1.000 <0.001 1.000
⑥ <0.001 0.046 1.000 0.001 <0.001 0.491 1.000 1.000
⑦ 1.000 0.192 <0.001 1.000 1.000 <0.001 <0.001 0.417
⑧ <0.001 1.000 1.000 0.075 <0.001 0.858 <0.001 <0.001
⑨ <0.001 1.000 0.020 <0.001 0.903 0.111 <0.001 <0.001
② ③ 0.003 1.000 0.183 1.000 1.000 1.000 1.000 1.000
④ 0.137 1.000 1.000 1.000 0.004 1.000 <0.001 1.000
⑤ 1.000 1.000 1.000 <0.001 <0.001 1.000 <0.001 1.000
⑥ <0.001 0.002 1.000 1.000 <0.001 1.000 0.058 1.000
⑦ 1.000 1.000 <0.001 0.101 1.000 <0.001 1.000 1.000
⑧ <0.001 1.000 0.569 1.000 <0.001 1.000 <0.001 <0.001
⑨ <0.001 1.000 1.000 0.186 <0.001 <0.001 <0.001 <0.001
③ ④ <0.001 1.000 1.000 1.000 <0.001 1.000 0.003 0.057
⑤ <0.001 1.000 1.000 0.056 <0.001 1.000 <0.001 0.118
⑥ <0.001 0.146 1.000 1.000 <0.001 1.000 1.000 1.000
⑦ 0.017 0.672 <0.001 1.000 0.027 <0.001 0.237 1.000
⑧ <0.001 1.000 1.000 1.000 <0.001 1.000 <0.001 <0.001
⑨ <0.001 1.000 1.000 0.001 <0.001 <0.001 <0.001 <0.001
④ ⑤ 1.000 1.000 1.000 0.011 1.000 0.339 <0.001 1.000
⑥ <0.001 <0.001 1.000 1.000 0.330 0.746 1.000 1.000
⑦ 0.048 1.000 <0.001 1.000 1.000 <0.001 <0.001 0.167
⑧ <0.001 1.000 1.000 1.000 <0.001 0.082 <0.001 0.005
⑨ 0.034 1.000 1.000 0.001 1.000 <0.001 <0.001 <0.001
⑤ ⑥ <0.001 0.074 1.000 <0.001 1.000 1.000 <0.001 1.000
⑦ 1.000 0.842 <0.001 1.000 0.179 <0.001 <0.001 0.315
⑧ <0.001 1.000 1.000 <0.001 <0.001 1.000 <0.001 0.006
⑨ <0.001 1.000 1.000 <0.001 1.000 <0.001 <0.001 <0.001
⑥ ⑦ <0.001 <0.001 <0.001 0.011 0.001 <0.001 <0.001 1.000
⑧ 1.000 0.014 1.000 1.000 0.074 1.000 <0.001 <0.001
⑨ 1.000 <0.001 1.000 1.000 0.625 <0.001 <0.001 <0.001
⑦ ⑧ <0.001 0.639 <0.001 0.443 <0.001 <0.001 <0.001 <0.001
⑨ <0.001 1.000 <0.001 <0.001 0.694 <0.001 <0.001 <0.001
⑧ ⑨ 0.001 1.000 1.000 0.002 <0.001 <0.001 1.000 1.000
Note: ①,②,③,④,⑤,⑥,⑦,⑧,⑨ is the serial number of each subgroup indicator in Table 2
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Comparison of the levels of serum blood lipids in the
seven subgroups of hematological diseases
In the seven hematological diseases group the levels of
oxLDL-IgG antibodies titer were statistically significant
in between-group comparisons including ①-②, ①-③,
②-⑤, ③-④, ③-⑤, ④-⑤, ④-⑦, ⑤-⑥ and ⑤-⑦ (P <
0.05); However, there was no significant difference for
the levels of oxLDL-IgM antibodies titer (P > 0.05).
Plasma oxLDL levels were statistically significant in be-
tween subsets comparisons including ①-②, ①-③, ②-⑦,
③-⑦, ③-⑦, ④-⑦ and ⑤-⑦ (P < 0.05).
A bivariate correlation analysis (Table 4) shows that
the oxLDL-IgG antibody titer is positively related to age,
BMI, systolic blood pressure (SBP), diastolic blood pres-
sure (DBP), TCH, LDL-c and oxLDL but inversely re-
lated to adiponectin (ADP) and triglyceride (TG);
Moreover, the levels of oxLDL-IgM antibody titer are
inversely related to age, BMI, DBP, TCH and LDL-c
and positively related to ADP and TG. It is noteworthy
that there is an inversely relationship between the
levels of oxLDL-IgM titer and the levels of oxLDL-IgM
titer (r = −0.368, P < 0.01).
Table 5 lists the correlation coefficients between the
levels of serum blood lipid (including TCH, TG, LDL-c
HDL-c, oxLDL and ADP) and the oxLDL-IgM /oxLDL-
IgG antibodies titer. In the hypertension group, the
levels of serum oxLDL-IgM titer are positively related to
ADP and TG and inversely related to the levels of serum
oxLDL; the levels of oxLDL-IgG antibody titer are posi-
tively related to the levels of serum LDL-c and TCH.
In the normal control group the levels of serum
oxLDL-IgM antibody titer are positively related to LDL-
c, ADP and TG and inversely related to the levels of
serum HDL-c; however, the levels of serum oxLDL-IgG
antibody titer are positively related to the levels of serum
HDL-c and inversely related to the levels of serum ADP.
In the seven subgroups of hematological diseases the
tendency of correlation is quite different. For example,
in the non-lymphatic leukemia group, the level of the
oxLDL-IgM antibody titer is positively related to the
levels of serum TCH, oxLDL-c and ADP but inversely
related to the levels of serum LDL-c; however, there is
not significant correlation between oxLDL-IgG antibody
titer among those study groups.
Multiple linear regression model analysis
Table 6 lists that the outcome of two multiple linear
regression model analyses, with the dependent vari-
able of the oxLDL-IgM and oxLDL-IgG antibody titer
respectively. Comparing with the normal controls, 7
subgroups of hematological diseases have the positive
relationship to the levels of serum oxLDL-IgM anti-
body titers but the negative relationship to the levels
of serum oxLDL-IgG antibody titers, having been ad-
justed for potential confounding variables such as age,
SBP, DBP, BMI, TCH, TG, ADP, oxLDL, HDL-c, LDL-
C and hypertension group.
Discussion
In the present study, we found out that (1) the profiles
of serum lipid including oxLDL-IgM and oxLDL-IgG are
consistent with the reported results in the literature [4, 5],
comparing with the normal controls; (2) the mean levels
of the serum lipid including TCH, TG, LDL-c, HDL-c,
oxLDL, oxLDL-IgG and oxLDL-IgM are lower and the
levels of ADP and oxLDL-IgM are higher in the patients
with seven types of hematological diseases, comparing
with normal controls; (3) the change in the trend of the
Table 4 The correlation coefficients of the measurement variables in the study
Group oxLDL-IgM oxLDL-IgG LDL-c HDL-c OxLDL ADP TG TCH SBP DBP BMI Age
Groupa 1.000
oxLDL-IgM −0.343** 1.000
oxLDL-IgG 0.494** −0.368** 1.000
LDL-c 0.293** −0.300** 0.301** 1.000
HDL-c 0.169** −0.084 −0.024 −0.225** 1.000
OxLDL 0.187** −0.008 0.237** −0.058 0.090 1.000
ADP −0.182** 0.482** −0.199** −0.182** 0.002 0.062
TG −0.048 −0.031 −0.157** 0.302** −0.221** −0.085 −0.050 1.000
TCH 0.417** −0.379** 0.287** 0.802** 0.239** 0.046 −0.213** 0.299** 1.000
SBP 0.051 −0.022 0.248** 0.106* 0.030 0.014 0.014 0.022 0.102* 1.000
DBP 0.367** −0.184** 0.390** 0.312** 0.106* 0.022 −0.184** 0.204** 0.432** 0.557** 1.000
BMI 0.225** −0.145** 0.227** 0.246** −0.035 0.003 −0.025 0.219** 0.282** 0.205** 0.302** 1.000
Age 0.258** −0.137** 0.142** 0.156** −0.111* −0.099 −0.091 −0.003 0.122* 0.315** 0.108* 0.120* 1.000
Gender −0.005 −0.056 0.003 0.124* 0.211** −0.087 −0.054 −0.078 0.211** −0.135** 0.086 −0.021 −0.099
aThe variable group consists of nine sub groups that listed in the Table 4; *:P < 0.05, **:P < 0.01
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profiles of serum lipid is the same as that of the normal
controls, comparing with the patients with hypertension.
The results suggest that the association tendency between
lipids and cardiovascular diseases is different from that be-
tween lipid and hematological diseases. At the same time
the levels of oxLDL-IgG have a significant difference
among the different hematological diseases, in particular
for leukemia. This result is consistent with our previous
report [18].
The immunoglobulin, the oxLDL-IgM and oxLDL-IgG
antibodies, are the origin of autoantibody production of
oxLDL. Therefore, it is reasonable to conclude that they
probably play a more important physiological role in
modulating the development of hematological diseases.
In view of the molecular immunology, it’s well known
that the molecule of the IgM antibody is relatively large
and responds sensitively to the recent infectious agent;
however, the molecule of the IgG antibody is relatively
Table 6 The main effects for the variables related to the dependent variable of oxLDL-IgM or oxLDL-IgG in the generated linear
regression modelsb
Parameters in the regression model Dependent Var oxLDL-IgM Dependent Var oxLDL-IgG
B Wald P B Wald P
Constant 13.281 7.294 0.007 69.359 52.451 <0.001
Gender (M/F) 0.054 0.003 0.956 5.797 8.663 0.003
cases with non lymphatic leukemia 5.418 7.315 0.007 −37.985 106.186 <0.001
cases with lymphatic leukemia 8.340 11.736 0.001 −47.171 110.637 <0.001
cases with Hemolytic anemia 11.541 18.090 <0.001 −44.355 71.523 <0.001
cases with immunothrombocytopenia 6.469 9.687 0.002 −26.003 39.866 <0.001
cases with multiple myeloma 8.833 15.391 <0.001 −16.732 13.011 <0.001
cases with non Kochkin’s 9.716 22.301 <0.001 −32.233 63.987 <0.001
cases with myelodysplastic syndrome 7.196 7.659 0.006 −57.709 161.408 <0.001
patients with primary hypertension 1.692 0.697 0.404 4.992 1.440 0.230
healthy normal personsa 0.0 . . 0.0 . .
aThe baseline level is healthy normal persons group
bIn the two regression models we adjusted for potential confounding factors including age, SBP, DBP, BMI, TCH, TG, ADP, oxLDL, HDL-c, LDL-C
Table 5 The correlation coefficients between blood lipid terms and xLDL-IgG/oxLDL-IgM antibodies titer in each sub-groups
Group IgG LDL-c HDL-c OXLDL ADP TCH TG
cases with non lymphatic leukemia, IgM −0.063 −0.259** −0.099 0.267** 0.473** −0.239* −0.176
IgG 1.000 0.133 −0.180 0.013 −0.082 0.003 −0.149
cases with lymphatic leukemia IgM −0.071 0.067 0.421* −0.168 0.392* 0.244 −0.125
IgG 1.000 0.110 −0.201 0.627** −0.128 −0.306 0.107
cases with hemolytic anemia IgM −0.246 −0.611** 0.425* −0.156 0.073 −0.832** 0.374
IgG 1.000 0.226 0.140 0.911** −0.112 0.436* −0.358
cases with immunothrombocytopenia IgM 0.067 −0.233 −0.167 0.517** 0.350* −0.600** −0.267
IgG 1.000 0.233 −0.800** −0.300 0.100 −0.383* −0.400*
cases with multiple myeloma IgM −0.263 0.408* 0.490* −0.207 0.503** 0.408* 0.531**
IgG 1.000 −0.944** −0.524** 0.296 −0.056 −0.944** −0.821**
cases with non Kochkin’s lymphoma IgM −0.417* −0.517** 0.683** 0.383* 0.351* −0.183 −0.433**
IgG 1.000 0.400* −0.533** 0.450** −0.243 −0.083 −0.067
cases with myelodysplastic syndrome IgM 0.264 −0.178 −0.067 0.584** 0.962** −0.042 −0.660**
IgG 1.000 −0.624** 0.529** 0.257 0.222 0.363* −0.186
patients with primary hypertension IgM 0.213 −0.198 0.168 −0.273* 0.433** −0.141 0.296*
IgG 1.000 0.320* −0.153 −0.065 0.030 0.276* 0.094
healthy normal control IgM −0.131 0.455** −0.396** 0.193 0.449** 0.031 0.390**
IgG 1.000 −0.198 0.330* −0.010 −0.499** 0.015 −0.212
*: P < 0.05, **: P < 0.01
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small and responds sensitively to the previous infectious
agent, indicating the host with an ability of immunity to
the agent.
To the best of our knowledge, no related work has
been reported previously. In our previous studies we
found that the cytotoxicity of oxLDL on vascular endo-
thelial cells line was lower than that on esophageal can-
cer cell and leukemia cell lines, as well as in patients
with squamous cell esophageal carcinoma with a higher
level of the oxLDL-IgM antibody titer and lower level of
the oxLDL-IgG antibody titer, comparing with the nor-
mal persons [15, 18, 20]. The concentrations of ox-LDL
required to induce apoptosis are usually >20 μg/m; these
concentrations are quite high and observed only in pa-
tients with acute coronary syndromes [21]. Low physio-
logic concentrations (<5 μg/ml) do not cause significant
apoptosis, and are associated with the cell proliferation
[22]. Our assay indicated that the cytotoxic effects of
oxLDL on K562/AO2 and EC-9706 were significantly
higher than that on cancer cells of HT29, OVCAR3 and
OVCAR5, HeLa, MCF7, A549 and PC3, when all afore-
mentioned cell lines treated by oxLDL with the doses
ranging from 100 to 300 μg/ml inhibited cell prolifera-
tions at dose- and time- dependence [23]. Combined
with the results of the present study, we put forward the
following hypothesis: oxLDL inducing autoimmune re-
sponse is not only involved in the development of ath-
erosclerosis or other vascular disease, but also related in
the process of cancer and other chronic diseases includ-
ing hematological diseases.
Oxidation of lipoproteins and oxidative processes gener-
ally play an important role in the initiation and progres-
sion of atherosclerotic lesions and the main mechanism is
associated with the inflammatory and immune responses
[24]. Recently, Lopes-Virella MF & Virella G presented a
review of the modified LDL including oxLDL auto anti-
bodies in relation of the adaptive immune response in ath-
erosclerosis (AS) [25]. We reviewed the literature reports
and divided them into three categories: first hypothesis,
oxLDL antibodies as an independent factors doctrine,
some reports indicated that oxLDL and its autoantibody
oxLDL-IgG can increase the risk of AS, but its autoanti-
body oxLDL-IgG may decrease the risk of AS [26]; Second
hypothesis, some reports contradicted this conclusion
[27], Third hypothesis, some reports suggested a humoral
immune response to the modified LDL (mLDL) can be
pathogenic rather than the protective factor [25, 28]. One
relatively large sample clinic data showed that the titer
levels of antibodies to oxLDL in the CAD patients without
and with acute coronary syndromes had not significant
differences [29]. So far, the mechanism of antibodies
of oxLDL or other mLDL associated with AS is still
unclear. The evidences supporting oxLDL antibodies
as the independent predictor for AS are summarized
as following:First, the IgG and IgM antibodies provide dir-
ectly protective effect due to the combining immune com-
plexes [30]. Second, the antibodies to oxLDL block the
uptake of oxLDL by macrophages and prevent the foam
cell formation [28]. Third, probably the oxLDLAbs di-
rected against some oxidized-phospholipid epitopes but
not against others play a major protective role [31]. Once
activated oxLDL antigen, T cells secrete a variety of cyto-
kines and Th1 and Th2 cells have been postulated to play
different roles in promoting inflammatory response [32].
The IgG and IgM antibodies are produced mainly due to
the modification forms of oxLDL, malondialdehyde-
modified LDL (MDA-LDL) and advanced glycosylation end
product-modified LDL (AGE-LDL) [32]. Freigang S. et al.
found that the antiatherogenic effect of immunization of
modified LDL is not primarily dependent on very high ti-
ters of antibodies but more likely to result from the activa-
tion of cellular immune responses [26]. Recently, the
results of some studies also showed that oxLDL auto anti-
body can be the cellular immune responses in the patho-
genic process of diseases [33–35]. OxLDL was lower,
whereas oxLDL-Ab was higher in patients without cardio-
vascular disease (CVD) comparing with those with CVD
[33]. The blood level of assessed antibodies was significantly
higher in stroke patients than in control group. However,
this phenomenon does not seem to protect patients against
cerebrovascular events [34]. Recently a report found that a
quiescent population of IgM+ plasma cells including
oxLDL-specific IgM antibody secreting cells in bone mar-
row also sustained the elevated IgM antibody response in
circulation [35]. One author reported that comparing with
the patients (aged >65 years) with OxLDL-Ab level ≥200
arbitrary U/ml, the Ox LDL-Ab level <200 arbitrary U/ml
Adjusted Hazard Ratio (HR) was 2.67 (95 % CI 1.58–4.52)
for composite outcome (hospitalization and mortality).
OxLDL-Ab level was the best indicator for both
hospitalization and composite outcome [36]. It is excited
that a new approach of determination OXLDL antibody
component, a novel single-chain variable fragments (scFvs)
γκ5, has been established and the γκ5 scFv can detect the
modified LDL at very low concentrations [37]. This will
promote the deep study of the relationship between oxLDL
antibodies and diseases.
The main limitation of this study is due to small sample
of patients with hematological diseases in cross-section
design, and still needs a large sample in prospective study
to get a strong evidence to support the idea. Also the
mechanism of the oxLDL and its auto-antibodies involved
the development of various hematological diseases needs
to be elucidated in the future.
Conclusions
Our data suggest that the trend of association between
lipids and cardiovascular diseases is different from that
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between lipid and hematological diseases. Also that the
common characters of the different hematological dis-
eases with the oxLDL-IgG antibody titers were lower,
while the oxLDL-IgM antibody titers were higher than
the normal group. Finally there were statistically signifi-
cant differences of the oxLDL-IgG antibody titers among
those hematological diseases. The results of this study
are useful for further study on etiology and serious com-
plications of hematological diseases.
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